Syros Pharmaceuticals Growth, Revenue, Number of Employees and Funding

Overview

Location:
Boston, MA USA
Total Funding:$165.8M
Industry:Pharma
Founded:2012
Lead Investor(s):JMP Securities LLC
Press

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Syros Pharmaceuticals's estimated revenue is currently $2.1M per year.
  • Syros Pharmaceuticals received $40.0M in venture funding in February 2018.
  • Syros Pharmaceuticals's estimated revenue per employee is $20297
  • Syros Pharmaceuticals's total funding is $165.8M.

Employee Data

  • Syros Pharmaceuticals has 101 Employees.
  • Syros Pharmaceuticals grew their employee count by 11% last year.
  • Syros Pharmaceuticals currently has 1 job openings.

Executive Contacts

NameTitle
Eric OlsonChief Scientific Officer
Matthew EatonAssociate Director, Computational Biology
Charlie PakVP of New Product Planning
Hina JolinAssociate Director
Anneli SavinainenDirector Preclinical Pharmacology and Toxicology
Keisha ThomasAssociate Director, Corporate Development
Graeme HodgsonSenior Director Translational Medicine
Sara MathewsAssociate Director, Clinical Science
John CarulliVice President, Biology
Tiffany CrowellVice President, Clinical Operations

What Is Syros Pharmaceuticals?

Syros is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, Syros gene control platform has broad potential to create medicines that achieve profound and durable benefit across a range of diseases. Syros is currently focused on cancer and monogenic diseases and is advancing a growing pipeline of gene control medicines. Syros lead drug candidates are SY-1425, a selective RAR agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor in a Phase 1 clinical trial for patients with advanced solid tumors. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.

keywords:Biotechnology,Healthcare,Marketing,Pharmaceuticals

101

Number of Employees

$2.1M

Revenue (est)

1

Current Jobs

11%

Employee Growth %

$165.8M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Vita Data Scien...
$7.8M4250%
Veristat
$38M22015%
TESARO
$176.1M9376%
Agios Pharmaceu...
$111.2M59214%
Adelphi Values
$24.7M1326%
Acer Therapeuti...
$5M3918%$29M
Opus Regulatory
$8.2M4429%
Boston Biomedic...
$29.9M15910%
Orbis Clinical
$7.4M4018%
Long Term Pharm...
$10.3M5510%

Syros Pharmaceuticals News

12-Sep-19 - Syros Pharmaceuticals moving HQ out of East Cambridge

The new facility will give the Cambridge-based biotech capacity to double its 80-person employee base. Subscribe to get the full story.

12-Sep-19 - Syros Pharmaceuticals Selects Igneous to Manage ...

Founded in 2012, Syros Pharmaceuticals is a pioneering life sciences company focused on a new area of medicine called gene therapy.

12-Sep-19 - Syros Pharmaceuticals (NASDAQ:SYRS) Lifted to Strong-Buy at BidaskClub

Syros Pharmaceuticals (NASDAQ:SYRS) was upgraded by investment analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a ...

Syros Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2013-04-12$30.0MAARCH Venture Partners, Flagship VenturesArticle
2014-10-28$53.0MBArticle
2016-01-13$40.0MUndisclosedDeerfield Management CompanyArticle
2017-04-24$35.0MUndisclosedSamsara BioCapitalArticle
2018-02-01$40.0MUndisclosedJMP Securities LLCArticle

Syros Pharmaceuticals Executive Hires

DateNameTitleReference
2013-05-23Eric R. OlsonChief Scientific OfficerArticle
2014-06-11Jorge CondeCFO/Chief Product OfficerArticle
2015-05-01Jonathan GarenChief Business OfficerArticle
2015-09-22Kyle KuvalankaCOOArticle
2015-12-08David A. RothChief Medical OfficerArticle
2016-09-27Gerald E QuirkChief Legal OfficerArticle
2017-01-31Peter WirthChairmanArticle
2017-11-14Jeremy SpringhornChief Business Officer.Article
2018-03-13Joseph FerraCFOArticle